IFNL4 and hepatocellular carcinoma: Among all REVEAL II patients, IFNL4 genotype was associated with progression to HCC (OR=1.79, p=0.011, Table 4), but this association was not significant after accounting for SVR after treatment or retreatment (Tables 4, 5).